{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-004924","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2023-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.077742+00:00","generated_at":"2026-06-17T00:00:47.567432+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CEL-SCI to pursue Health Canada's conditional approval pathway for Multikine in head & neck cancer","bullets":["Health Canada advised CEL-SCI to request approval under Notice of Compliance with Conditions (NOC/c) policy for Multikine.","Plans to file drug submission for earlier access in Canada while preparing U.S. BLA and pursuing other country approvals.","Phase 3 IT-MATTERS study in head & neck cancer showed median OS improvement of 46.5 months for lower-risk patients.","Five-year survival: 62.7% for Multikine vs 48.6% control; tumor shrinkage >30% in ~1 of 6 patients in 3 weeks.","5 patients had complete tumor disappearance in 3 weeks prior to surgery."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-004924","json":"https://secwatch.observer/filing/0001654954-23-004924.json","markdown":"https://secwatch.observer/filing/0001654954-23-004924.md","text":"https://secwatch.observer/filing/0001654954-23-004924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495423004924/0001654954-23-004924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495423004924/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T00:00:47.567432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}